Keyphrases
Galectin-3 (Gal-3)
100%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
Patients with Heart Failure
100%
Three-level
31%
Spironolactone
25%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
18%
Confidence Interval
12%
Hazard Ratio
12%
VO2peak
12%
All-cause Mortality
12%
NYHA Class
12%
All-cause Hospitalization
12%
Quality of Life
6%
Placebo
6%
Functional Performance
6%
Level Characteristic Values
6%
Multivariable
6%
Myocardial Fibrosis
6%
Patient Characteristics
6%
Worse Outcome
6%
Physical Functioning
6%
Short Form 36 (SF-36)
6%
Aldosterone
6%
Once-daily
6%
Velocity Ratio
6%
Diastolic Dysfunction
6%
Functional Quality
6%
6-minute Walk Distance (6MWD)
6%
Cardiovascular Inflammation
6%
LV Mass Index
6%
Left Atrial Volume Index
6%
Stable Heart Failure
6%
Cardiovascular Fibrosis
6%
Clinical Outcomes
6%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure with Preserved Ejection Fraction
100%
Galectin 3
100%
Spironolactone
25%
Heart Muscle Fibrosis
6%
Placebo
6%
Cardiovascular Inflammation
6%
Diastolic Dysfunction
6%
Fibrosis
6%
Aldosterone
6%
Biochemistry, Genetics and Molecular Biology
Galectin-3
100%
Heart Ejection Fraction
100%
Spironolactone
25%
Aldosterone
6%